.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
UBS
Baxter
Boehringer Ingelheim
Johnson and Johnson
Farmers Insurance
Chinese Patent Office
Mallinckrodt
Citi

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204467

« Back to Dashboard

NDA 204467 describes ALLOPURINOL, which is a drug marketed by Accord Hlthcare, Apotex Inc, Indoco Remedies, Ipca Labs Ltd, Mutual Pharm, Mylan, Northstar Hlthcare, Puracap Pharm, Purepac Pharm, Sandoz, Sun Pharm Inds Inc, Sun Pharm Industries, Superpharm, Vintage Pharms, Watson Labs, Zydus Pharms Usa Inc, and West-ward Pharms Int, and is included in twenty-six NDAs. It is available from forty-two suppliers. Additional details are available on the ALLOPURINOL profile page.

The generic ingredient in ALLOPURINOL is allopurinol sodium. There are twenty-one drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the allopurinol sodium profile page.

Summary for 204467

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Therapeutic Class:Antigout Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 204467

Mechanism of ActionXanthine Oxidase Inhibitors

Suppliers and Packaging for NDA: 204467

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ALLOPURINOL allopurinol TABLET;ORAL 204467 ANDA Ingenus Pharmaceuticals LLC 50742-135 50742-135-01 100 TABLET in 1 BOTTLE (50742-135-01)
ALLOPURINOL allopurinol TABLET;ORAL 204467 ANDA Ingenus Pharmaceuticals LLC 50742-135 50742-135-05 500 TABLET in 1 BOTTLE (50742-135-05)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength100MG
Approval Date:Jul 28, 2016TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength300MG
Approval Date:Jul 28, 2016TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Healthtrust
Mallinckrodt
Johnson and Johnson
Moodys
Cipla
Federal Trade Commission
Harvard Business School
Citi
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot